HY-110086 Search Results


sch529074 compound  (MedChemExpress)
93
MedChemExpress sch529074 compound
(A) Western blot generated from NCI-H1975 cell lysates. Cells were treated with 6µM <t>SCH529074</t> compound (+) or mock DMSO (-) for 24 hours. Expression of p53 and p21 is shown. Vinculin was included as a loading control. (B) Differential isoform expression for CDKN1A (encoding p21) upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (C) Differential isoform expression for TPX2 and NCAPG upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (D) Signaling pathway enrichment analysis on the top 100 isoform targets (87 unique genes) of TP53 in LUAD against 343 KEGG pathways. Only pathways with Hypergeometric test P<0.05 are shown. (E) Survival analysis based on the mutation status of TP53 in LUAD cancer. (F) Survival analysis based on the expression level of two representative isoform targets of TP53 in LUAD as indicated. LUAD tumor samples were divided into 3 tiers equally based on expression level of each isoform, and only the high (n=171) and low (n=171) tiers were kept for comparison. (G) Differential expression analysis for two representative isoform targets of TP53 between normal (n=59) and tumor (n=517) LUAD samples. (H) A representative result of the cell cycle analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. (I) Cell apoptosis analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. Percent of cells are presented as MeanSD for 2 replicates. P-values for survival analysis were derived from log-rank test; Significance levels for differential analysis were derived from Wilcoxon rank-sum test (for TCGA data) or t -test (for H1975 cell line data), **** P <1e-4, *** P <1e-3, ** P <0.01, * P <0.05, ns: non-significant. See also and .
Sch529074 Compound, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sch529074 compound/product/MedChemExpress
Average 93 stars, based on 1 article reviews
sch529074 compound - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
btzo 1 concentrations  (MedChemExpress)
92
MedChemExpress btzo 1 concentrations
(A) Western blot generated from NCI-H1975 cell lysates. Cells were treated with 6µM <t>SCH529074</t> compound (+) or mock DMSO (-) for 24 hours. Expression of p53 and p21 is shown. Vinculin was included as a loading control. (B) Differential isoform expression for CDKN1A (encoding p21) upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (C) Differential isoform expression for TPX2 and NCAPG upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (D) Signaling pathway enrichment analysis on the top 100 isoform targets (87 unique genes) of TP53 in LUAD against 343 KEGG pathways. Only pathways with Hypergeometric test P<0.05 are shown. (E) Survival analysis based on the mutation status of TP53 in LUAD cancer. (F) Survival analysis based on the expression level of two representative isoform targets of TP53 in LUAD as indicated. LUAD tumor samples were divided into 3 tiers equally based on expression level of each isoform, and only the high (n=171) and low (n=171) tiers were kept for comparison. (G) Differential expression analysis for two representative isoform targets of TP53 between normal (n=59) and tumor (n=517) LUAD samples. (H) A representative result of the cell cycle analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. (I) Cell apoptosis analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. Percent of cells are presented as MeanSD for 2 replicates. P-values for survival analysis were derived from log-rank test; Significance levels for differential analysis were derived from Wilcoxon rank-sum test (for TCGA data) or t -test (for H1975 cell line data), **** P <1e-4, *** P <1e-3, ** P <0.01, * P <0.05, ns: non-significant. See also and .
Btzo 1 Concentrations, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/btzo 1 concentrations/product/MedChemExpress
Average 92 stars, based on 1 article reviews
btzo 1 concentrations - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
rwj 50271  (MedChemExpress)
N/A
   Buy from Supplier

Image Search Results


(A) Western blot generated from NCI-H1975 cell lysates. Cells were treated with 6µM SCH529074 compound (+) or mock DMSO (-) for 24 hours. Expression of p53 and p21 is shown. Vinculin was included as a loading control. (B) Differential isoform expression for CDKN1A (encoding p21) upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (C) Differential isoform expression for TPX2 and NCAPG upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (D) Signaling pathway enrichment analysis on the top 100 isoform targets (87 unique genes) of TP53 in LUAD against 343 KEGG pathways. Only pathways with Hypergeometric test P<0.05 are shown. (E) Survival analysis based on the mutation status of TP53 in LUAD cancer. (F) Survival analysis based on the expression level of two representative isoform targets of TP53 in LUAD as indicated. LUAD tumor samples were divided into 3 tiers equally based on expression level of each isoform, and only the high (n=171) and low (n=171) tiers were kept for comparison. (G) Differential expression analysis for two representative isoform targets of TP53 between normal (n=59) and tumor (n=517) LUAD samples. (H) A representative result of the cell cycle analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. (I) Cell apoptosis analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. Percent of cells are presented as MeanSD for 2 replicates. P-values for survival analysis were derived from log-rank test; Significance levels for differential analysis were derived from Wilcoxon rank-sum test (for TCGA data) or t -test (for H1975 cell line data), **** P <1e-4, *** P <1e-3, ** P <0.01, * P <0.05, ns: non-significant. See also and .

Journal: PLOS Computational Biology

Article Title: iSoMAs: Finding isoform expression and somatic mutation associations in human cancers

doi: 10.1371/journal.pcbi.1012847

Figure Lengend Snippet: (A) Western blot generated from NCI-H1975 cell lysates. Cells were treated with 6µM SCH529074 compound (+) or mock DMSO (-) for 24 hours. Expression of p53 and p21 is shown. Vinculin was included as a loading control. (B) Differential isoform expression for CDKN1A (encoding p21) upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (C) Differential isoform expression for TPX2 and NCAPG upon TP53 mutation in both clinical (TCGA-LUAD) and cell line (NCI-H1975) samples as indicated. (D) Signaling pathway enrichment analysis on the top 100 isoform targets (87 unique genes) of TP53 in LUAD against 343 KEGG pathways. Only pathways with Hypergeometric test P<0.05 are shown. (E) Survival analysis based on the mutation status of TP53 in LUAD cancer. (F) Survival analysis based on the expression level of two representative isoform targets of TP53 in LUAD as indicated. LUAD tumor samples were divided into 3 tiers equally based on expression level of each isoform, and only the high (n=171) and low (n=171) tiers were kept for comparison. (G) Differential expression analysis for two representative isoform targets of TP53 between normal (n=59) and tumor (n=517) LUAD samples. (H) A representative result of the cell cycle analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. (I) Cell apoptosis analysis for NCI-H1975 cells under various treatment conditions at different time points as indicated. Percent of cells are presented as MeanSD for 2 replicates. P-values for survival analysis were derived from log-rank test; Significance levels for differential analysis were derived from Wilcoxon rank-sum test (for TCGA data) or t -test (for H1975 cell line data), **** P <1e-4, *** P <1e-3, ** P <0.01, * P <0.05, ns: non-significant. See also and .

Article Snippet: Culture medium was replaced with medium containing 6 µM SCH529074 compound (MedChemExpress, Cat. No. HY-110088) or an equivalent volume of DMSO (mock treatment).

Techniques: Western Blot, Generated, Expressing, Control, Mutagenesis, Comparison, Quantitative Proteomics, Cell Cycle Assay, Derivative Assay